G8 Education Limited (ASX:GEM) Announces 2025 AGM Highlights
G8 Education Limited (ASX:GEM) reports a 14.8% EBIT increase and highlights strategic initiatives during its 2025 AGM.
G8 Education Limited (ASX:GEM) reports a 14.8% EBIT increase and highlights strategic initiatives during its 2025 AGM.
Radiopharm Theranostics (ASX:RAD) initiates Phase 2b U.S. trial of 18F-RAD101, advancing diagnostic capabilities for brain metastasis.
Unibail-Rodamco-Westfield (ASX:URW) reports strong Q1 2025 performance, confirms earnings guidance, and completes significant asset disposals.
NOVONIX (ASX:NVX) appoints Michael O’Kronley as CEO, marking a significant leadership change within the company.
Orthocell (ASX:OCC) receives Thai FDA approval to launch Remplir™, expanding into the US$84 million nerve repair market.
Lynas Rare Earths Ltd (ASX:LYC) reports Q1 FY25 sales revenue of A$123m and initiates production of Dysprosium, reinforcing its strategic position in the rare earths market.
Eagle Mountain Mining (ASX:EM2) completes rights issue, raising A$5.9 million and advancing key projects.
Surefire Resources NL (ASX:SRN) extends Yidby gold mineralisation, advances copper systems, secures offtake agreement, and receives R&D rebate.
Future Battery Minerals (ASX:FBM) announces key gold targets at Kal North and expands Western Australia landholdings, enhancing exploration prospects.
Australian Rare Earths Limited (ASX:AR3) finalises farm-in agreement for EL6678, expanding its Overland Uranium Project with promising exploration results.